Paxil and allergy medication combinations are a common concern for patients managing both mental health conditions and allergic symptoms. In the UK, Paxil is known as Seroxat (paroxetine), a prescription SSRI used to treat depression, anxiety, OCD, and PTSD. Many people also take allergy treatments — from antihistamines to nasal sprays — often purchased over the counter without consulting a healthcare professional. Understanding how paroxetine interacts with different allergy medicines is essential for avoiding preventable side effects, particularly excessive sedation, anticholinergic effects, and, in specific cases, cardiac risks. This article outlines what UK patients and carers need to know.

What Is Paroxetine and How Is It Used in the UK?

Paroxetine — known by the brand name Seroxat in the UK, and sometimes referred to by its US brand name Paxil — is a prescription-only medicine belonging to the selective serotonin reuptake inhibitor (SSRI) class of antidepressants. It works by blocking the reabsorption of serotonin in the brain, thereby increasing serotonin availability in the synaptic cleft. This mechanism helps regulate mood, anxiety, and emotional responses over time.

In the UK, paroxetine is licensed and prescribed for a range of mental health conditions, including:

• Major depressive disorder (NICE NG222)

• Generalised anxiety disorder (GAD) (NICE CG113)

• Panic disorder (NICE CG113)

• Social anxiety disorder (NICE CG159)

• Obsessive-compulsive disorder (OCD) (NICE CG31)

• Post-traumatic stress disorder (PTSD) (NICE NG116)

Paroxetine is available in tablet and liquid form and is typically taken once daily, usually in the morning with food. It is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA), and prescribing is informed by the relevant NICE clinical guidelines listed above. As with all SSRIs, therapeutic effects generally develop over two to four weeks, and patients are advised not to stop taking the medication abruptly without medical guidance, as this can cause discontinuation symptoms. Paroxetine is notably associated with a higher risk of discontinuation effects compared with other SSRIs — a point highlighted in NICE guidance and the Seroxat Summary of Product Characteristics (SmPC).

Paroxetine has important contraindications and interactions that prescribers must consider, including concurrent use of monoamine oxidase inhibitors (MAOIs) and certain other medicines such as pimozide and thioridazine. Patients should refer to the Seroxat SmPC (available via the MHRA/eMC) and the NHS medicines page for paroxetine for a full list of contraindications and interactions.

Common Allergy Medications Available in the UK

Allergy medications are widely used across the UK to manage conditions such as hay fever, allergic rhinitis, urticaria (hives), and allergic conjunctivitis. They are available both over the counter (OTC) at pharmacies and on prescription, depending on the formulation and indication.

The most commonly used allergy treatments in the UK include:

• Antihistamines: These are a first-line treatment for most allergic conditions. They are divided into first-generation (sedating) antihistamines, such as chlorphenamine (Piriton) and promethazine, and second-generation (non-sedating) antihistamines, such as cetirizine, loratadine, and fexofenadine. Second-generation antihistamines are generally preferred due to their reduced sedative effects. Hydroxyzine is a sedating antihistamine available on prescription; the MHRA issued a Drug Safety Update in 2015 restricting its use due to a risk of QT prolongation, and it should be used with caution or avoided in patients with known QT risk factors or those taking other medicines that affect cardiac rhythm.

• Intranasal corticosteroids: Sprays such as beclometasone (Beconase) and fluticasone (Flixonase) are recommended as first-line treatment for allergic rhinitis by NICE CKS and are available OTC or on prescription. They have negligible systemic absorption and are the preferred option for persistent or moderate-to-severe rhinitis symptoms.

• Decongestants: Pseudoephedrine (oral) and xylometazoline (topical nasal spray) are used for nasal congestion associated with allergies. Topical nasal decongestants such as xylometazoline should be limited to 5–7 days of use to avoid rebound congestion (rhinitis medicamentosa).

• Leukotriene receptor antagonists: Montelukast is a prescription medicine sometimes used as an add-on treatment for allergic rhinitis and asthma; it is not a routine first-line option for allergic rhinitis. The MHRA issued a Drug Safety Update in 2019 highlighting the risk of neuropsychiatric reactions (including sleep disturbances, mood changes, and suicidal ideation) with montelukast. Patients and carers should be counselled about these risks before starting treatment.

Many of these medications are purchased without a prescription, meaning patients may not always inform their GP or pharmacist when combining them with prescribed medicines such as paroxetine. Patients should also be aware that many OTC 'allergy' products are combination preparations containing both an antihistamine and a decongestant; taking these alongside a separately purchased antihistamine risks unintentional double-dosing. Always check the label and seek pharmacist advice before combining products.

Interactions Between Paroxetine and Allergy Treatments

Understanding potential interactions between paroxetine and allergy medications is essential for safe prescribing and patient self-management. The nature and severity of interactions vary considerably depending on the type of allergy treatment involved.

Sedating antihistamines and paroxetine: First-generation antihistamines such as chlorphenamine and promethazine have significant central nervous system (CNS) depressant and anticholinergic properties. When combined with paroxetine, which can itself cause drowsiness and cognitive slowing, the sedative and anticholinergic effects may be additive. This combination can impair concentration, reaction times, and the ability to drive or operate machinery safely. Patients should avoid alcohol when taking this combination, as alcohol further increases CNS depression.

Non-sedating antihistamines: Second-generation antihistamines differ in their interaction potential with paroxetine. Cetirizine and fexofenadine undergo minimal cytochrome P450 metabolism and have a low interaction risk with paroxetine. Loratadine is metabolised partly via CYP3A4 and CYP2D6; whilst paroxetine is a potent CYP2D6 inhibitor, a clinically significant interaction with loratadine is considered unlikely at standard doses, though patients should be monitored for any increase in side effects. Overall, second-generation antihistamines are preferred when allergy treatment is needed alongside paroxetine.

Intranasal corticosteroids: Preparations such as beclometasone and fluticasone nasal sprays have negligible systemic absorption and no clinically relevant pharmacokinetic interaction with paroxetine. They are the preferred first-line option for allergic rhinitis in patients taking paroxetine.

Decongestants: Pseudoephedrine and similar sympathomimetic agents can increase blood pressure and heart rate. Caution is advised when combining oral decongestants with SSRIs such as paroxetine, particularly in patients with uncontrolled hypertension or cardiovascular disease. Topical nasal decongestants (e.g., xylometazoline) have lower systemic absorption but should still be limited to short courses of 5–7 days.

Montelukast: There is no well-established pharmacokinetic interaction between montelukast and paroxetine. However, both medicines can independently affect mood and behaviour. Given the MHRA's 2019 warning on neuropsychiatric reactions with montelukast, patients and clinicians should remain alert to any changes in mood, sleep, or behaviour when both are used concurrently, and seek prompt medical review if such changes occur.

For detailed interaction information, clinicians and pharmacists should consult the BNF interactions section, individual SmPCs, and Specialist Pharmacy Service (SPS/UKMi) guidance on managing interactions between SSRIs and OTC medicines.

Risks and Side Effects to Be Aware Of

Both paroxetine and certain allergy medications carry their own side effect profiles, and combining them may increase the likelihood or severity of some adverse effects. Being informed about these risks supports safer self-management and timely reporting to a healthcare professional.

Paroxetine side effects commonly include:

• Nausea, dry mouth, and constipation

• Drowsiness or insomnia

• Increased sweating

• Sexual dysfunction

• Weight changes

• Discontinuation symptoms if stopped abruptly

Sedating antihistamines may cause:

• Drowsiness and impaired alertness

• Dry mouth and urinary retention

• Blurred vision

• Confusion, particularly in older adults

When paroxetine is combined with sedating antihistamines, the risk of excessive sedation and anticholinergic effects is the primary concern. Patients should not drive or operate machinery if they feel drowsy, and should avoid alcohol. This is particularly relevant for older patients, who may be more sensitive to CNS depressant effects and at greater risk of falls. Older adults taking SSRIs are also at increased risk of hyponatraemia (low sodium); if they develop confusion, unusual fatigue, or seizures, they should seek prompt medical advice.

QT prolongation: Hydroxyzine carries a specific MHRA restriction regarding QT prolongation risk (MHRA Drug Safety Update, 2015), and should be avoided or used with caution in patients with QT risk factors or those taking other QT-prolonging medicines. Paroxetine itself has a relatively low QT liability compared with other antidepressants such as citalopram or escitalopram, but the combination with hydroxyzine warrants caution. Other commonly used antihistamines (cetirizine, loratadine, fexofenadine, chlorphenamine) do not carry the same level of QT concern as hydroxyzine.

Serotonin syndrome is a potentially serious condition caused by excessive serotonergic activity. Standard H1 antihistamines — including promethazine — are not serotonergic agents and do not meaningfully increase the risk of serotonin syndrome when combined with paroxetine. The risk of serotonin syndrome is more relevant when paroxetine is combined with other serotonergic medicines such as MAOIs, linezolid, tramadol, triptans, or dextromethorphan. Patients should be aware of symptoms such as agitation, confusion, rapid heart rate, high temperature, and muscle twitching, and seek urgent medical attention if these occur — particularly if they are also taking any of the medicines listed above.

Patients are encouraged to report any suspected side effects from their medicines — including interactions — via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

Guidance From NHS and MHRA on Combining These Medicines

In the UK, both the NHS and the MHRA provide guidance to support the safe use of medicines, including when combining prescription drugs with OTC treatments. Whilst there is no single dedicated NHS guideline specifically addressing paroxetine and allergy medication combinations, relevant safety information is embedded across several authoritative sources.

The MHRA regularly reviews drug interaction data and updates the Summary of Product Characteristics (SmPC) for medicines such as paroxetine (Seroxat), available via the eMC (medicines.org.uk). The Seroxat SmPC advises caution when co-administering medicines that affect the CNS and highlights paroxetine's potent inhibition of CYP2D6 as a key pharmacokinetic consideration. The MHRA has also issued Drug Safety Updates on hydroxyzine (2015, QT prolongation) and montelukast (2019, neuropsychiatric reactions) that are directly relevant to patients using allergy medicines alongside paroxetine.

NICE guidelines recommend that clinicians conduct a full medicines review when initiating or reviewing SSRIs, including asking patients about OTC and herbal medicines. Relevant guidance includes NG222 (depression in adults), CG113 (GAD and panic disorder), CG159 (social anxiety disorder), CG31 (OCD), and NG116 (PTSD). NICE CKS: Allergic rhinitis confirms that intranasal corticosteroids and second-generation oral antihistamines are first-line treatments, which is particularly relevant when selecting allergy treatments for patients already taking paroxetine.

The NHS website advises patients taking paroxetine to inform their GP or pharmacist before taking any new medicines, including those bought over the counter. It specifically notes that sedating antihistamines may increase drowsiness when taken alongside SSRIs. The NHS medicines page for paroxetine provides patient-facing interaction and side-effect information.

Pharmacists in the UK play a vital role in identifying potential interactions at the point of sale. Under professional standards set by the General Pharmaceutical Council (GPhC) Standards for Pharmacy Professionals, pharmacists are required to provide appropriate advice when dispensing or recommending medicines, including flagging interaction risks. The BNF and Specialist Pharmacy Service (SPS/UKMi) resources provide further clinical detail to support pharmacists and prescribers in managing these interactions.

When to Speak to a GP or Pharmacist

Knowing when to seek professional advice is a key aspect of safe medicines management. Patients taking paroxetine who wish to use allergy medications — whether prescribed or purchased OTC — should not assume that all combinations are automatically safe.

You should speak to a pharmacist before purchasing any allergy medication if you:

• Are currently taking paroxetine or any other antidepressant

• Are unsure whether a product contains a sedating antihistamine or is a combination antihistamine–decongestant preparation

• Have a history of heart rhythm problems or are taking other medicines that affect the heart

• Are elderly or caring for an elderly person who takes paroxetine

• Have been prescribed montelukast and notice any changes in mood, sleep, or behaviour

Contact your GP promptly if you experience:

• Unusual or excessive drowsiness after starting an allergy medication

• Increased anxiety, agitation, or restlessness

• A rapid or irregular heartbeat

• Confusion or disorientation

• Any new or worsening mental health symptoms, including mood or sleep changes

For urgent advice, contact NHS 111 (by phone or online at 111.nhs.uk). Call 999 or go to A&E for severe or life-threatening symptoms, including signs of a serious allergic reaction or any sudden, severe deterioration.

Seek urgent medical attention if you notice signs of serotonin syndrome, including high temperature, muscle stiffness or twitching, agitation, or loss of coordination. This is uncommon with standard allergy medications but is more relevant if paroxetine is combined with other serotonergic medicines such as MAOIs, tramadol, triptans, or dextromethorphan-containing cough remedies.

It is always advisable to carry an up-to-date medicines list to share with any healthcare professional, including pharmacists. Patients in England can access the New Medicine Service through community pharmacies when starting a new prescribed medicine, and Structured Medication Reviews through their GP practice — both provide an opportunity to discuss concerns about drug combinations in a supported, non-urgent setting. Equivalent services may be available under different arrangements in Scotland, Wales, and Northern Ireland; ask your GP surgery or pharmacy for local options. Open communication with your healthcare team remains the most effective safeguard when managing multiple medicines.

If you experience a suspected side effect from any medicine, please report it via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or using the Yellow Card app.

Frequently Asked Questions